Previous close | 65.77 |
Open | 65.77 |
Bid | 68.00 |
Ask | 75.60 |
Strike | 330.00 |
Expiry date | 2025-01-17 |
Day's range | 65.77 - 65.77 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Is Eli Lilly stock a buy after the company said its weight-loss drug reduced the risk of developing diabetes by 94%?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the humanized amyloid-beta (Aβ) monoclonal antibody "Leqembi®" (brand name, generic name: lecanemab) has been granted a Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain.1 Lecanemab is indicated for the treatment of mild cognitive imp